NCT07160790: Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease
- State
- Not started
- Phase
- Phase 3
- People
- 321 planned
- Started
- 2 Sep 2025
- Primary completion
- 30 Jun 2026
- Arms
- Group 1: JP-1366 A mg + Placebo, Group 2: JP-1366 B mg + Placebo
- Results
- None posted
- 8 Sep 2025: Trial registered